Semler Scientific, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income
Reconciliation of Net Income to Net Cash Provided by Operating Activities:
Depreciation
Deferred tax expense (income)
Loss on disposal of assets for lease
Write off of prepaid software licenses
Gain on short-term investments
Loss on disposal of inventory
Allowance for credit losses
Non-cash interest income
Gain on sale of Mellitus Health Inc. securities
Change in fair value of notes held for investment
Change in fair value of digital assets
Stock-based compensation
Impairment of long-term investments
Changes in Operating Assets and Liabilities:
Trade accounts receivable
Inventory
Prepaid expenses and other current assets
Other non-current assets
Accounts payable
Accrued expenses
Deferred revenue
Other current and non-current liabilities

Net Cash Provided by Operating Activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment
Payment for long-term note receivable from SYNAPS Dx
Payment for long-term note receivable from Mellitus Health Inc.
Purchase of shares of preferred stock from Mellitus Health Inc.
Proceeds from sale of Mellitus Health Inc.
Notes receivable
Purchase of notes held for investment
Purchase of digital assets
Proceeds from maturities of short-term investments
Purchase of short-term investments
Purchase of assets for lease
Proceeds from sale (purchase) of assets for lease
Net Cash (Used in) Provided by Investing Activities

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock
Taxes paid related to net settlement of equity awards
Common stock warrants acquired
Treasury stock acquired
Stock issuance expenses
Proceeds from exercise of stock options
Net Cash Provided by (Used in) Financing Activities
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS
CASH, BEGINNING OF PERIOD
CASH, END OF PERIOD
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD
Supplemental Disclosure of Cash Flow Information:
Cash paid for taxes
Long-term note receivable from SYNAPS Dx settled by stock issuance
Exchange of SMLR common stock for preferred stock of Private company #2
Exchange of SMLR common stock for preferred stock of SYNAPS Dx
Exercised put option of 211,928 common stock in SYNAPS Dx for 40,922 common stock of the company
Long-term note receivable from Mellitus Health Inc. settled by stock issuance

Comments